Cargando…
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
Non-small cell lung cancer (NSCLC), caused by various mutations in a spectrum of cancer driver genes, may have distinct pathological characteristics and drug responses. Extensive genetic screening and pathological characterization is required for the design of customized therapies to improve patient...
Autores principales: | DONG, YU, REN, WEIHONG, QI, JUN, JIN, BO, LI, YING, TAO, HUIQING, XU, REN, LI, YANQING, ZHANG, QINXIAN, HAN, BAOHUI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812214/ https://www.ncbi.nlm.nih.gov/pubmed/27073482 http://dx.doi.org/10.3892/ol.2016.4235 |
Ejemplares similares
-
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014) -
EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer
por: REN, WEIHONG, et al.
Publicado: (2015) -
Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013) -
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019) -
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)